Homburger advises Ginkgo Bioworks in its acquisition of FGen

Ginkgo Bioworks, a horizontal platform for cell programming, entered into a definitive purchase agreement to acquire FGen, a Swiss company specializing in strain development and optimization.

Ginkgo Bioworks believes that FGen’s technology will significantly enhance Ginkgo’s cell screening capabilities and enable Ginkgo to explore wider expanses of genetic opportunity space, increasing the likelihood of finding enzymes, pathways, and strains or cell lines that perform to diverse product specifications.

Under the terms of the transaction, FGen will receive upfront payment and additional contingent consideration related to, among other things, the successful integration and deployment of the FGen technology across Ginkgo programs.

Homburger has advised Ginkgo Bioworks with regard to all Swiss legal aspects of the transaction. The Homburger Team has been led by partner Daniel Hasler (pictured) and includes associates Angela Oppliger, Karin Mattle and junior associate Benjamin Camavdic (all corporate / m&a), partner Reto Heuberger and associate Philippe Weber (both tax) as well as associate Kirsten Wesiak–Schmidt (IP / IT).